---
title: "Astellas Pharma Inc. (ALPMY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALPMY.US.md"
symbol: "ALPMY.US"
name: "Astellas Pharma Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T03:06:55.619Z"
locales:
  - [en](https://longbridge.com/en/quote/ALPMY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALPMY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALPMY.US.md)
---

# Astellas Pharma Inc. (ALPMY.US)

## Company Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.astellas.com](https://www.astellas.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: B (0.32)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 10 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 12.42% |  |
| Net Profit YoY | 477.35% |  |
| P/B Ratio | 2.26 |  |
| Dividend Ratio | 3.38% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 25887063128.10 |  |
| Revenue | 14097077934.10 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 17.45% | A |
| Profit Margin | 13.63% | B |
| Gross Margin | 80.91% | A |
| Revenue YoY | 12.42% | B |
| Net Profit YoY | 477.35% | A |
| Total Assets YoY | 0.16% | D |
| Net Assets YoY | 13.46% | B |
| Cash Flow Margin | 192.15% | B |
| OCF YoY | 12.42% | B |
| Turnover | 0.62 | B |
| Gearing Ratio | 48.67% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Astellas Pharma Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "12.42%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "477.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.26",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.38%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "25887063128.10",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "14097077934.10",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "17.45%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "13.63%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "80.91%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "12.42%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "477.35%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.16%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "13.46%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "192.15%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "12.42%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.62",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "48.67%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.58 | 21/190 | 38.15 | 30.32 | 13.53 |
| PB | 2.28 | 99/190 | 2.39 | 2.02 | 1.78 |
| PS (TTM) | 1.85 | 47/190 | 1.95 | 1.64 | 1.42 |
| Dividend Yield | 3.36% | 9/190 | 4.82% | 3.97% | 3.01% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-26T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.56 |
| Highest Target | 19.00 |
| Lowest Target | 19.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALPMY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALPMY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ALPMY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALPMY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**